Consistent with the results of previous studies of COX-2 inhibitors, the cumulative incidence of ulcer complications was reduced by 79% among patients who received lumiracoxib ( P < 0.0001), but the reduction was smaller and did not reach statistical significance among patients who received concomitant aspirin.
← all excerpts
Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
1
—
—